Skip to main content
. Author manuscript; available in PMC: 2009 Sep 14.
Published in final edited form as: Ann Intern Med. 2008 Aug 19;149(4):242–250. doi: 10.7326/0003-4819-149-4-200808190-00005

Table 3.

Adjusted odds ratios for hip fractures according to vitamin D quartiles

1st (9.23 − <47.6 nM) (N = 244) 2nd (47.6 − <60.2 nM) (N = 195) 3rd (60.2 − < 40.7 nM) (N =167) 4th (70.7 − 121.5 nM) (N =193) P for linear trend
Base Analysis
Odds Ratio & 95% CI 1.71 (1.05 − 2.79) 1.09 (0.70 − 1.71) 0.82 (0.51 − 1.31) 1.00 (ref) 0.016
P 0.032 0.760 0.453
Base Analysis + Adjusted for Frailty †† Score
Odds Ratio & 95% CI 1.65 (1.01 − 2.69) 1.08 (0.68 − 1.70) 0.81 (0.50 − 1.30) 1.00 (ref) 0.022
P 0.047 0.744 0.375
Base Analysis + Adjusted for RAND 36 Physical Functioning >90
Odds Ratio & 95% CI 1.68 (1.02 − 2.76) 1.15 (0.73 − 1.83) 0.81 (0.50− 1.31) 1.00 (ref) 0.016
P 0.041 0.550 0.392
Base Analysis + Adjusted for Total Number of Falls during follow-up
Odds Ratio & 95% CI 1.66 (1.00 − 2.77) 1.14 (0.70 − 1.85) 0.86 (0.52 − 1.42) 1.00 (ref) 0.018
P 0.039 0.594 0.551
Base Analysis + Adjusted for Bioavailable Estradiol
Odds Ratio & 95% CI 1.75 (1.06 − 2.87) 1.01 (0.64 − 1.59) 0.75 (0.46 − 1.23) 1.00 (ref) 0.022
P 0.028 0.976 0.253
Base Analysis + Adjusted for Bioavailable Testosterone
Odds Ratio & 95% CI 1.72 (1.05 − 2.83) 1.05 (0.67 − 1.66) 0.82 (0.50 − 1.34) 1.00 (ref) 0.021
P 0.031 0.830 0.422
Base Analysis + Adjusted for cystatin-C
Odds Ratio & 95% CI 1.68 (1.02 − 2.76) 1.18 (0.70 − 1.76) 0.81 (0.50 − 1.31) 1.00 (ref) 0.019
P 0.042 0.658 0.389
Base Analysis + Adjusted for PINP* Odds Ratio & 95% CI 1.69 (1.04 − 2.77) 1.05 (0.67 − 1.67) 0.84 (0.52 − 1.35 1.00 (ref) 0.022
P 0.036 0.822 0.472
Base Analysis + Adjusted for CTx* Odds Ratio & 95% CI 1.58 (0.97 − 2.60) 1.03 (0.66 − 1.64) 0.83 (0.51 − 1.34) 1.00 (ref) 0.040
P 0.069 0.890 0.441
Summary MV model** Odds Ratio & 95% CI 1.72 (0.98 − 3.02) 1.21 (0.71 − 2.05) 0.84 (0.48 − 1.46) 1.00 (ref) 0.029
P 0.060 0.481 0.533
*

Abbreviations: PINP, amino proterminal procollagen extension propeptide; CTx, serum c terminal telopeptide of type I collagen.

Matched on age, ethnicity, blood draw date, controlled for age, BMI, parental history of hip fracture, history of fracture, smoking, alcohol use, and total calcium intake (from diet, supplement and medications, per 100 mg increase), oral corticosteroid use, geographic region.

**

Matched on age, ethnicity, blood draw date, controlled for age, BMI, parental history of hip fracture, history of fracture, smoking, alcohol use, and total calcium intake (from diet, supplement and medications, per 100 mg increase), oral corticosteroid use, geographic region, frailty, total number of falls, bioavailable estradiol, bioavailable testosterone, cystatin-C, PINP, and CTx.

††

Frailty was defined a 3 or more of the following criteria: muscle weakness, slow walking speed, exhaustion, low physical activity and unintentional weight loss (23).